{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:03:05Z","timestamp":1788822185127,"version":"build-2803163510"},"reference-count":166,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kosciuszko Foundation (KF) Special","award":["2023"],"award-info":[{"award-number":["2023"]}]},{"name":"Kosciuszko Foundation (KF) Special","award":["2023"],"award-info":[{"award-number":["2023"]}]},{"name":"Polish\u2013American Medical Society in Chicago (PAMS)","award":["2023"],"award-info":[{"award-number":["2023"]}]},{"name":"Polish\u2013American Medical Society in Chicago (PAMS)","award":["2023"],"award-info":[{"award-number":["2023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chimerism-based strategies represent a pioneering concept which has led to groundbreaking advancements in regenerative medicine and transplantation. This new approach offers therapeutic potential for the treatment of various diseases, including inherited disorders. The ongoing studies on chimeric cells prompted the development of Dystrophin-Expressing Chimeric (DEC) cells which were introduced as a potential therapy for Duchenne Muscular Dystrophy (DMD). DMD is a genetic condition that leads to premature death in adolescent boys and remains incurable with current methods. DEC therapy, created via the fusion of human myoblasts derived from normal and DMD-affected donors, has proven to be safe and efficacious when tested in experimental models of DMD after systemic\u2013intraosseous administration. These studies confirmed increased dystrophin expression, which correlated with functional and morphological improvements in DMD-affected muscles, including cardiac, respiratory, and skeletal muscles. Furthermore, the application of DEC therapy in a clinical study confirmed its long-term safety and efficacy in DMD patients. This review summarizes the development of chimeric cell technology tested in preclinical models and clinical studies, highlighting the potential of DEC therapy in muscle regeneration and repair, and introduces chimeric cell-based therapies as a promising, novel approach for muscle regeneration and the treatment of DMD and other neuromuscular disorders.<\/jats:p>","DOI":"10.3390\/biom14050575","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T08:59:37Z","timestamp":1715677177000},"page":"575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9150-9974","authenticated-orcid":false,"given":"Katarzyna","family":"Budzynska","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6122","authenticated-orcid":false,"given":"Maria","family":"Siemionow","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA"},{"name":"Chair and Department of Traumatology, Orthopaedics, and Surgery of the Hand, Poznan University of Medical Sciences, 61-545 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Stawarz","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3377-3284","authenticated-orcid":false,"given":"Lucile","family":"Chambily","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Siemionow","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook, Springer.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00005-015-0380-8","article-title":"Immunomodulatory Effects of Different Cellular Therapies of Bone Marrow Origin on Chimerism Induction and Maintenance across MHC Barriers in a Face Allotransplantation Model","volume":"64","author":"Hivelin","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Silk, A.D., Gast, C.E., Davies, P.S., Fakhari, F.D., Vanderbeek, G.E., Mori, M., and Wong, M.H. (2013). Fusion between hematopoietic and epithelial cells in adult human intestine. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055572"},{"key":"ref_4","first-page":"24","article-title":"The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation","volume":"11","author":"Mousavi","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nature01539","article-title":"Transplanted bone marrow regenerates liver by cell fusion","volume":"422","author":"Vassilopoulos","year":"2003","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nm1040","article-title":"Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation","volume":"10","author":"Nygren","year":"2004","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1073\/pnas.0508593103","article-title":"Bone marrow-derived cells fuse with normal and transformed intestinal stem cells","volume":"103","author":"Rizvi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/sci-2020-044","article-title":"Development of Donor Recipient Chimeric Cells of bone marrow origin as a novel approach for tolerance induction in transplantation","volume":"8","author":"Cwykiel","year":"2021","journal-title":"Stem Cell Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/TP.0000000000003006","article-title":"Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization","volume":"104","author":"Lee","year":"2020","journal-title":"Transplantation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-5699(88)91352-7","article-title":"Mixed allogeneic chimerism as an approach to transplantation tolerance","volume":"9","author":"Sykes","year":"1988","journal-title":"Immunol. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/TP.0000000000004589","article-title":"Chimerism-based Tolerance Induction in Clinical Transplantation: Its Foundations and Mechanisms","volume":"107","author":"Mengrelis","year":"2023","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a015529","DOI":"10.1101\/cshperspect.a015529","article-title":"Induction of Tolerance through Mixed Chimerism","volume":"4","author":"Sachs","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.990","article-title":"Regenerative Solutions for Inherited Diseases","volume":"103","author":"Tolar","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/SAP.0b013e3181877ad7","article-title":"Correlation of chimerism with graft size and revascularization in vascularized and nonvascularized skin allografts","volume":"62","author":"Nasir","year":"2009","journal-title":"Ann. Plast. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/01.PRS.0000079823.84984.BB","article-title":"A new composite facial and scalp transplantation model in rats","volume":"112","author":"Ulusal","year":"2003","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00005-021-00614-9","article-title":"Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts","volume":"69","author":"Cwykiel","year":"2021","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","article-title":"Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy","volume":"14","author":"Siemionow","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/scd.2020.0161","article-title":"Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast\/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model","volume":"30","author":"Siemionow","year":"2021","journal-title":"Stem Cells Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/sci-2022-026","article-title":"Creation of human hematopoietic chimeric cell (HHCC) line as a novel strategy for tolerance induction in transplantation","volume":"9","author":"Siemionow","year":"2022","journal-title":"Stem Cell Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/sci-2023-024","article-title":"Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression","volume":"10","author":"Siemionow","year":"2023","journal-title":"Stem Cell Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","article-title":"Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy","volume":"14","author":"Siemionow","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/aian.aian_20_23","article-title":"Development and Validation of an Outpatient Clinical Predictive Score for the Diagnosis of Duchenne Muscular Dystrophy\/Becker Muscular Dystrophy in Children Aged 2-18 Years","volume":"26","author":"Sharawat","year":"2023","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The Pathogenesis and Therapy of Muscular Dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1276144","DOI":"10.3389\/fped.2023.1276144","article-title":"Detecting early signs in Duchenne muscular dystrophy: Comprehensive review and diagnostic implications","volume":"11","author":"Mercuri","year":"2023","journal-title":"Front. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","article-title":"Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England","volume":"20","author":"Cheetham","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1756285615586123","article-title":"Duchenne muscular dystrophy: Current cell therapies","volume":"8","author":"Sienkiewicz","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/14712598.2015.1057564","article-title":"Cell therapy in muscular dystrophies: Many promises in mice and dogs, few facts in patients","volume":"15","author":"Skuk","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2016.163","article-title":"Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs","volume":"24","author":"Sitzia","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/hmg\/ddv316","article-title":"Long-term engraftment of myogenic progenitors from adipose-derived stem cells and muscle regeneration in dystrophic mice","volume":"24","author":"Zhang","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1111\/febs.12083","article-title":"Perspectives of stem cell therapy in Duchenne muscular dystrophy","volume":"280","author":"Meregalli","year":"2013","journal-title":"FEBS J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kumar","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12026-007-0013-3","article-title":"Chimerism and tetragametic chimerism in humans: Implications in autoimmunity, allorecognition and tolerance","volume":"38","author":"Yunis","year":"2007","journal-title":"Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nri.2017.38","article-title":"Immunological implications of pregnancy-induced microchimerism","volume":"17","author":"Kinder","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103971","DOI":"10.1016\/j.ejmg.2020.103971","article-title":"Natural human chimeras: A review","volume":"63","author":"Madan","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/172603a0","article-title":"Actively acquired tolerance of foreign cells","volume":"172","author":"Billingham","year":"1953","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1098\/rstb.1959.0008","article-title":"Quantitative studies on tissue transplantation immunity IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease","volume":"242","author":"Billingham","year":"1959","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/307168a0","article-title":"Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts","volume":"307","author":"Ildstad","year":"1984","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.smim.2011.07.001","article-title":"Immuno-intervention for the induction of transplantation tolerance through mixed chimerism","volume":"23","author":"Sachs","year":"2011","journal-title":"Semin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007890-198612000-00004","article-title":"Prolongation of renal allograft survival in antilymphocyte-serum-treated dogs by postoperative injection of density-gradient-fractionated donor bone marrow","volume":"42","author":"Hartner","year":"1986","journal-title":"Transplantation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00000658-198309000-00013","article-title":"Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression","volume":"198","author":"Thomas","year":"1983","journal-title":"Ann. Surg."},{"key":"ref_45","first-page":"384","article-title":"Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt","volume":"79","author":"Monaco","year":"1976","journal-title":"Surgery"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/bmj.1.6059.471","article-title":"Orthotopic liver transplantation: The first 60 patients","volume":"1","author":"Calne","year":"1977","journal-title":"Br. Med. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa074191","article-title":"Tolerance and chimerism after renal and hematopoietic-cell transplantation","volume":"358","author":"Scandling","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMc1107841","article-title":"Induced immune tolerance for kidney transplantation","volume":"365","author":"Scandling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199306000-00012","article-title":"Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation","volume":"55","author":"Starzl","year":"1993","journal-title":"Transplantation"},{"key":"ref_50","first-page":"341","article-title":"The dichotomous functions of passenger leukocytes in solid-organ transplantation","volume":"24","author":"Demetris","year":"1995","journal-title":"Adv. Nephrol. Necker Hosp."},{"key":"ref_51","first-page":"591","article-title":"In vivo chimera model: Creation of primary and secondary chimera","volume":"Volume 581","author":"Cwykiel","year":"2015","journal-title":"Plastic and Reconstructive Surgery: Experimental Models and Research Designs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bdrc.10017","article-title":"Stem cell plasticity, cell fusion, and transdifferentiation","volume":"69","author":"Eisenberg","year":"2003","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"Joly","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.humimm.2006.11.001","article-title":"Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells","volume":"68","author":"LeMaoult","year":"2007","journal-title":"Hum. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2006-05-024547","article-title":"Immune regulation by pretenders: Cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells","volume":"109","author":"LeMaoult","year":"2007","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.181.4.2271","article-title":"Cutting edge: In vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression","volume":"181","author":"Young","year":"2008","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.1104799","article-title":"Unveiling the mechanisms of cell-cell fusion","volume":"308","author":"Chen","year":"2005","journal-title":"Science"},{"key":"ref_58","unstructured":"Schwann, T. (1839). Mikroskopische Untersuchungen uber die Ubereinstimmung in der Struktur und dem Wachsten der Thiere und Pflanzen, Saunderschen Buchhandlung."},{"key":"ref_59","first-page":"1269","article-title":"\u201cHybrid\u201d type cells in combined cultures of two different mammalian cell strains","volume":"26","author":"Barski","year":"1961","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature730","article-title":"Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion","volume":"416","author":"Terada","year":"2002","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nature729","article-title":"Changing potency by spontaneous fusion","volume":"416","author":"Ying","year":"2002","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mitra, S., and Tomar, P.C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. J. Genet. Eng. Biotechnol., 19.","DOI":"10.1186\/s43141-021-00264-6"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0092-8674(02)01078-4","article-title":"Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury","volume":"111","author":"LaBarge","year":"2002","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nature01531","article-title":"Cell fusion is the principal source of bone-marrow-derived hepatocytes","volume":"422","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1172\/JCI21301","article-title":"Hematopoietic myelomonocytic cells are the major source of hepatocyte fusion partners","volume":"113","author":"Camargo","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nm1062","article-title":"Myelomonocytic cells are sufficient for therapeutic cell fusion in liver","volume":"10","author":"Willenbring","year":"2004","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature02069","article-title":"Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes","volume":"425","author":"Pardal","year":"2003","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3389\/fimmu.2019.01246","article-title":"Bone Marrow Transplantation 1957\u20132019","volume":"10","author":"Simpson","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14712598.2017.1316713","article-title":"Advances in umbilical cord blood cell therapy: The present and the future","volume":"17","author":"Berglund","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102952","DOI":"10.1016\/j.transci.2020.102952","article-title":"Umbilical cord blood: Current uses for transfusion and regenerative medicine","volume":"59","author":"Orlando","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1002\/sctm.20-0495","article-title":"Umbilical cord blood transplantation: Still growing and improving","volume":"10","author":"Zhu","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s12015-023-10608-z","article-title":"Human Multi-Chimeric Cell (HMCC) Therapy as a Novel Approach for Tolerance Induction in Transplantation","volume":"19","author":"Siemionow","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2014A world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e010040","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","article-title":"Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy","volume":"16","author":"Soslow","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-Skipping in Duchenne Muscular Dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"37051","DOI":"10.1038\/srep37051","article-title":"Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells","volume":"6","author":"Maggio","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9\u2013mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy","volume":"19","author":"Lamothe","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Sun, C., Shen, L., Zhang, Z., and Xie, X. (2020). Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes, 11.","DOI":"10.3390\/genes11080837"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevEukaryotGeneExpr.2015011074","article-title":"Cell therapy in Duchenne muscular dystrophy treatment: Clinical trials overview","volume":"25","author":"Bajek","year":"2015","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.15252\/emmm.201505636","article-title":"Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy","volume":"7","author":"Cossu","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s00018-013-1396-z","article-title":"Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy","volume":"70","author":"Govoni","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_87","first-page":"141","article-title":"Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Duchenne Muscular Dystrophy: Safety and Feasibility Study in India","volume":"10","author":"Rajput","year":"2015","journal-title":"J. Stem Cells"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3727\/000000007783465064","article-title":"Autologous Transplantation of Muscle-Derived CD133+ Stem Cells in Duchenne Muscle Patients","volume":"16","author":"Torrente","year":"2007","journal-title":"Cell Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1089\/scd.2016.0136","article-title":"Prosurvival Factors Improve Functional Engraftment of Myogenically Converted Dermal Cells into Dystrophic Skeletal Muscle","volume":"25","author":"Muir","year":"2016","journal-title":"Stem Cells Dev."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Miura, Y., Sato, M., Kuwahara, T., Ebata, T., Tabata, Y., and Sakurai, H. (2022). Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266391"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy","volume":"323","author":"Sun","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/sctm.21-0054","article-title":"Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle\u2019s function in Duchenne muscular dystrophy","volume":"10","author":"Siemionow","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1007\/s12015-022-10384-2","article-title":"Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy","volume":"18","author":"Siemionow","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_94","first-page":"399","article-title":"Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy","volume":"18","author":"Malik","year":"2022","journal-title":"Postepy Kardiol. Interwencyjnej"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","article-title":"Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy","volume":"15","author":"Siemionow","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00005-022-00656-7","article-title":"Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model","volume":"70","author":"Siemionow","year":"2022","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Siemionow, M., Budzynska, K., Zalants, K., Langa, P., Brodowska, S., Siemionow, K., and Heydemann, A. (2024). Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030586"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s12015-023-10530-4","article-title":"Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up","volume":"19","author":"Heydemann","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1007\/s12015-023-10620-3","article-title":"Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12-Month Follow-Up Study After Systemic Intraosseous Administration","volume":"19","author":"Siemionow","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00005-023-00691-y","article-title":"Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration","volume":"71","author":"Niezgoda","year":"2023","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Fu, X., Liu, G., Halim, A., Ju, Y., Luo, Q., and Song, A.G. (2019). Mesenchymal Stem Cell Migration and Tissue Repair. Cells, 8.","DOI":"10.3390\/cells8080784"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2011.06.011","article-title":"Hematopoietic stem and progenitor cell trafficking","volume":"32","author":"Mazo","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0000000000001191","article-title":"An update on Becker muscular dystrophy","volume":"36","author":"Straub","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","article-title":"Becker muscular dystrophy severity is linked to the structure of dystrophin","volume":"24","author":"Nicolas","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_105","first-page":"1735","article-title":"Facioscapulohumeral Muscular Dystrophy","volume":"28","author":"Mul","year":"2022","journal-title":"Continuum"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/1566523220666200218113526","article-title":"Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches","volume":"19","author":"Taheri","year":"2020","journal-title":"Curr. Gene Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13052-016-0289-9","article-title":"Congenital muscular dystrophy: From muscle to brain","volume":"42","author":"Falsaperla","year":"2016","journal-title":"Ital. J. Pediatr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.rdc.2011.01.002","article-title":"Polymyositis and dermatomyositis: Pathophysiology","volume":"37","author":"Nagaraju","year":"2011","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0019-5154.100486","article-title":"Clinical presentation and evaluation of dermatomyositis","volume":"57","author":"Marvi","year":"2012","journal-title":"Indian J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/ced.14689","article-title":"The chameleon rash: A review of the polyphenotypic dermatoses of dermatomyositis","volume":"46","author":"Connolly","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","article-title":"Therapy of polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2016.05.002","article-title":"Stem cell transplantation and mesenchymal cells to treat autoimmune diseases","volume":"45","author":"Tyndall","year":"2016","journal-title":"Presse Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ard.2010.141804","article-title":"Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis","volume":"70","author":"Wang","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kok, K., Zwiers, K.C., Boot, R.G., Overkleeft, H.S., Aerts, J.M.F.G., and Artola, M. (2021). Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules, 11.","DOI":"10.3390\/biom11020271"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.humpath.2011.09.020","article-title":"Cardiac and skeletal myopathy in Fabry disease: A clinicopathologic correlative study","volume":"43","author":"Chimenti","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/8904_2014_342","article-title":"Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: Consensus on the approach to diagnosis and follow-up","volume":"17","author":"Cassiman","year":"2014","journal-title":"JIMD Rep."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Perretta, F., and Jaurretche, S. (2023). Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?. Healthcare, 11.","DOI":"10.3390\/healthcare11040449"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: Pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/01.gim.0000217789.14470.c5","article-title":"Physical therapy management of Pompe disease","volume":"8","author":"Case","year":"2006","journal-title":"Genet. Med."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"MENA Pompe Working Group, Al Jasmi, F., Al Jumah, M., Alqarni, F., Al-Sanna\u2019a, N., Al-Sharif, F., Bohlega, S., Cupler, E.J., Fathalla, W., and Hamdan, M.A. (2015). Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: Consensus recommendations from an expert group. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0412-3"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): An update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: Recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"Stok","year":"2010","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Unnisa, Z., Yoon, J.K., Schindler, J.W., Mason, C., and van Til, N.P. (2022). Gene Therapy Developments for Pompe Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020302"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","article-title":"Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing","volume":"134","author":"Domm","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40279-014-0223-5","article-title":"McArdle disease: A unique study model in sports medicine","volume":"44","author":"Santalla","year":"2014","journal-title":"Sports Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Llavero, F., Arrazola Sastre, A., Luque Montoro, M., G\u00e1lvez, P., Lacerda, H.M., Parada, L.A., and Zugaza, J.L. (2019). McArdle Disease: New Insights into Its Underlying Molecular Mechanisms. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235919"},{"key":"ref_134","first-page":"e44701","article-title":"A Case Report of McArdle Disease Diagnosed Following Statin-Induced Myositis","volume":"15","author":"Teles","year":"2023","journal-title":"Cureus"},{"key":"ref_135","first-page":"CD003458","article-title":"Pharmacological and nutritional treatment for McArdle\u2019s disease (Glycogen Storage Disease type V)","volume":"11","author":"Quinlivan","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: Clinical features, evaluation, and management","volume":"7","author":"Levandowski","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Shalata, A., Bar-Shai, M., Hadid, Y., Mahroum, M., Mintz, H., Shalata, Z.E., Radzishevsky, E., Genizi, J., Lorber, A., and Ben-Yosef, T. (2023). Danon Disease: Entire LAMP2 Gene Deletion with Unusual Clinical Presentation-Case Report and Review of the Literature. Genes, 14.","DOI":"10.3390\/genes14081539"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1355.e23","DOI":"10.1016\/j.cjca.2016.02.071","article-title":"Identification of Two Novel LAMP2 Gene Mutations in Danon Disease","volume":"32","author":"Popoiu","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1038\/cddis.2016.475","article-title":"Autophagy dysregulation in Danon disease","volume":"8","author":"Nascimbeni","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ortu\u00f1o-Costela, M.D.C., Cerrada, V., Moreno-Izquierdo, A., Garc\u00eda-Consuegra, I., Laberthonni\u00e8re, C., Delourme, M., Garesse, R., Arenas, J., Fuster Garc\u00eda, C., and Garc\u00eda Garc\u00eda, G. (2022). Generation of the First Human In Vitro Model for McArdle Disease Based on iPSC Technology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213964"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Zhang, J., Chou, O.H., Tse, Y.L., Ng, K.M., and Tse, H.F. (2021). Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158132"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/sctm.19-0375","article-title":"Unleashing the cure: Overcoming persistent obstacles in the translation and expanded use of hematopoietic stem cell-based therapies","volume":"9","author":"Talib","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"ref_144","first-page":"386","article-title":"Mechanisms of neurodegeneration in amyotrophic lateral sclerosis","volume":"54","author":"Cluskey","year":"2001","journal-title":"Mol. Pathol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"van den Bos, M.A.J., Geevasinga, N., Higashihara, M., Menon, P., and Vucic, S. (2019). Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112818"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1789.2003.00544.x","article-title":"Amyotrophic lateral sclerosis with dementia: The clinicopathological spectrum","volume":"24","author":"Yoshida","year":"2004","journal-title":"Neuropathology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrneurol.2013.203","article-title":"The epidemiology of ALS: A conspiracy of genes, environment and time","volume":"9","author":"Hardiman","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"132933","DOI":"10.1016\/j.neulet.2017.06.052","article-title":"The role of mitochondria in amyotrophic lateral sclerosis","volume":"710","author":"Smith","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1212\/CPJ.0000000000001124","article-title":"Embedded Palliative Care for Amyotrophic Lateral Sclerosis: A Pilot Program and Lessons Learned","volume":"12","author":"Zapata","year":"2022","journal-title":"Neurol. Clin. Pract."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-824535-4.00007-0","article-title":"Palliative care principles in ALS","volume":"191","author":"Shoesmith","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7S3","DOI":"10.1016\/S0929-693X(20)30269-4","article-title":"Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA)","volume":"27","author":"Lefebvre","year":"2020","journal-title":"Arch. Pediatr."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: Going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"942976","DOI":"10.3389\/fncel.2022.942976","article-title":"History of development of the life-saving drug \u201cNusinersen\u201d in spinal muscular atrophy","volume":"16","author":"Qiu","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","article-title":"Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis","volume":"40","author":"Fox","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","article-title":"iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders","volume":"29","author":"Okano","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4103\/1673-5374.206635","article-title":"Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease","volume":"12","author":"Jaiswal","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_158","first-page":"915","article-title":"Neural Stem Cells and Human Induced Pluripotent Stem Cells to Model Rare CNS Diseases","volume":"16","author":"Zalfa","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1152\/physrev.00061.2017","article-title":"Sarcopenia: Aging-Related Loss of Muscle Mass and Function","volume":"99","author":"Larsson","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Picca, A., and Calvani, R. (2021). Molecular Mechanism and Pathogenesis of Sarcopenia: An Overview. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063032"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1074\/mcp.RA117.000124","article-title":"Novel Sarcopenia-related Alterations in Sarcomeric Protein Post-translational Modifications (PTMs) in Skeletal Muscles Identified by Top-down Proteomics","volume":"17","author":"Wei","year":"2018","journal-title":"Mol. Cell. Proteom."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Dowling, P., Gargan, S., Swandulla, D., and Ohlendieck, K. (2023). Fiber-Type Shifting in Sarcopenia of Old Age: Proteomic Profiling of the Contractile Apparatus of Skeletal Muscles. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032415"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3892\/ijmm.2021.4989","article-title":"Pathophysiology and mechanisms of primary sarcopenia (Review)","volume":"48","author":"Nishikawa","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3346\/jkms.2022.37.e146","article-title":"A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction","volume":"37","author":"Cho","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13287-022-02706-5","article-title":"The role and therapeutic potential of stem cells in skeletal muscle in sarcopenia","volume":"13","author":"Cai","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_166","first-page":"429","article-title":"Therapeutic potential of mesenchymal stem cells and their derivatives in sarcopenia","volume":"44","author":"Wong","year":"2022","journal-title":"Malays. J. Pathol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/5\/575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:30Z","timestamp":1760107290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/5\/575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":166,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["biom14050575"],"URL":"https:\/\/doi.org\/10.3390\/biom14050575","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}